UBS Group’s DataMeds AI MEDS Stock Holding History

UBS Group’s Portfolio MEDS Stock Details MEDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-319	Closed	-$6.37K	–	11527
2025 Q4	$6.37K	Sell	319 -534	-63%	-$15.7K	﹤0.01%	8559
2025 Q3	$37.8K	Buy	+853	New	+$45K	﹤0.01%	7758
2025 Q2	–	Sell	-59	Closed	-$12.8K	–	11118
2025 Q1	$12.8K	Buy	+59	New	+$9.95K	﹤0.01%	8479

Other funds holding MEDS

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

ACT Advisors Asheville, North Carolina $301M AUM 23.36% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

UBS Group's MEDS Position: Q1 2026 in Review

UBS Group sold out of DataMeds AI (MEDS) in Q1 2026, closing a stake of 319 shares — an estimated $6.37K sold.

UBS Group first reported a position in MEDS in Q1 2025 and held it in 3 quarters. The position peaked at $37.8K in Q3 2025. 13 funds tracked by Wall St. Rank hold MEDS as of Q1 2026.

UBS Group reported no remaining DataMeds AI position as of Q1 2026 after selling out during the quarter.
UBS Group sold 319 DataMeds AI shares in Q1 2026, an estimated $6.37K.
UBS Group first reported a position in DataMeds AI in Q1 2025 and held it in 3 quarters.
UBS Group's DataMeds AI position peaked at $37.8K in Q3 2025.
13 funds tracked by Wall St. Rank held DataMeds AI as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.